EPAC vs JBLU

EPAC presents a stark contrast between a healthy balance sheet and a severely overvalued market price. While the Piotroski F-Score of 4/9 indicates stable financial health and the company maintains strong margins and low debt, the stock is trading at a massive premium to its Graham Number ($16.82) and Intrinsic Value ($11.13). This valuation gap is exacerbated by negative earnings growth (-18.4% YoY) and a completely bearish technical trend (0/100). Despite strong ROE, the lack of earnings momentum and the significant distance from defensive fair value suggest limited upside and high downside risk.

JetBlue (JBLU) exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is burdened by excessive leverage (Debt/Equity of 4.44) and a liquidity crisis, with a current ratio of 0.74 and a quick ratio of 0.57. Negative profit margins and a catastrophic YoY EPS decline of -276.9% suggest the business model is currently unsustainable. While the stock trades below book value (P/B 0.86), this appears to be a value trap given the lack of growth and deteriorating balance sheet.